loxoprofen

Small moleculeexperimental

Loxoprofen is a nonsteroidal anti-inflammatory drug (NSAID) in the propionic acid derivatives group, which also includes ibuprofen and naproxen among others. It is available in some countries for oral administration. A transdermal preparation was approved for sale in Japan in January 2006; medicated tape and gel formulations followed in 2008 and 2010. — Wikipedia

Clinical trial activity

16 trials · 22 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
10
Phase 3
5
Phase 4
2

Earliest trial started Oct 1, 2004 (NCT00141154)

Timeline

2000s

  1. Jan 1, 2004

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2008

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2011

    Earliest Phase 2 Sponsor(trial)

Indications

Approved for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CC(C(=O)O)c1ccc(CC2CCCC2=O)cc1
Mol. weight
246.31 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No
Delivery
Oral

Oral

Yes

Parenteral

No

Topical

No

Prodrug

Sources

Also known as

  • 156-s
  • 2-(4-((2-oxocyclopentyl)methyl)phenyl)propionic acid
  • 2-ocppp
  • cs 600
  • cs-600
  • loxonin
  • loxoprofen
  • loxoprofen
  • loxoprofen
  • loxoprofen
  • loxoprofen
  • loxoprofen
  • loxoprofen
  • loxoprofen
  • loxoprofen alcohol
  • loxoprofen sodium
  • loxoprofen sodium
  • loxoprofen sodium
  • loxoprofen sodium dihydrate
  • loxoprofen sodium hydrate
  • loxoprofen sodium hydrate
  • loxoprofen sodium hydrate
  • loxoprofen sodium hydrate
  • loxoprofen sodium hydrate
  • loxoprofen sodium, (r*,s*)-isomer
  • sodium 2-(4-(2-oxocyclopentylmethyl)phenyl)propionate dihydrate
  • sodium loxoprofen
  • sodium loxoprofen

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06047483Phase 2Oct 31, 2023Hengrui Therapeutics, Inc.
NCT04386122Phase 1May 7, 2020Hanoi Medical University
NCT03386149Phase 3Dec 28, 2017Daegu Haany University, Dongguk University, Kyung Hee University
NCT02983747N/ANov 1, 2016Second Military Medical University
NCT02831569Phase 3Jul 1, 2016Boehringer Ingelheim
NCT02602353Phase 2Oct 1, 2015Cardinal Health, Jean Brown Research, Lead Chemical Co.,Ltd.
NCT02616068Phase 3Oct 1, 2015Daiichi Sankyo, IQVIA
NCT02384928N/ASep 9, 2015Jaseng Hospital of Korean Medicine
NCT02467504Phase 2Jul 1, 2015Beijing Sl Pharma Co Ltd, Monash University, Peking University
NCT03800797Phase 4May 25, 2015Sun Yat-Sen University
NCT01922466Phase 2Jul 1, 2013Korea Institute of Oriental Medicine, Kyung Hee University
NCT01779271Phase 3Jan 1, 2013Daewon Pharmaceutical Co., Ltd.
NCT01491321Phase 2Apr 1, 2011Kyung Hee University
NCT00994461Phase 4Nov 1, 2009Pfizer
NCT00676117Phase 1Apr 1, 2008AstraZeneca, Osaka Pharmacology Clinical Research Hospital
NCT00141154Phase 3Oct 1, 2004Pfizer
Showing 16 of 16 trials
Page 1 / 1

Organizations

Research & Development (22)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Kyung Hee UniversityAcademic/Hospital3322011
PfizerFor profit2222004
AstraZenecaFor profit1112008
Beijing Sl Pharma Co LtdFor profit1012015
Boehringer IngelheimFor profit1112016
Cardinal HealthAcademic/Hospital1012015
Daegu Haany UniversityAcademic/Hospital1012017
Daewon Pharmaceutical Co., Ltd.For profit1112013
Daiichi SankyoFor profit1112015
Dongguk UniversityAcademic/Hospital1012017
Hanoi Medical UniversityAcademic/Hospital1112020
Hengrui Therapeutics, Inc.For profit1112023
IQVIAFor profit1012015
Jaseng Hospital of Korean MedicineAcademic/Hospital1112015
Jean Brown ResearchFor profit1012015
Korea Institute of Oriental MedicineAcademic/Hospital1012013
Lead Chemical Co.,Ltd.For profit1112015
Monash UniversityAcademic/Hospital1012015
Osaka Pharmacology Clinical Research HospitalAcademic/Hospital1012008
Peking UniversityAcademic/Hospital1112015
22 organizations
Page 1 / 2